1.
Relationship between plasminogen activator inhibitor 1 and neuroblastoma
纤溶酶原激活物抑制物1与神经母细胞瘤
2.
Change and Implication of PAI-1 in Coronary Heart Disease Patients after Glucose Load
冠心病患者糖负荷后纤溶酶原激活物抑制物-1的变化及意义
3.
The Effect of Astragalus and Safflower Mixture on Expression of Plasminogen Activator Inhibitor 1 in Renal Tubulointerstitial Fibrosis in Rats with Unilateral Ureteral Obstruction;
芪红合剂对肾间质纤维化模型大鼠肾组织中纤溶酶原激活物抑制物-1表达的影响
4.
Plasma Concentrations of Matrix Metalloproteinase-9 and Plasminogen Activator Inhibitor-1 in Acute Coronary Syndromes;
急性冠脉综合征金属蛋白酶-9与纤溶酶原激活物抑制物-1的关系研究
5.
The Varity and Mechnisim of the Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes with Hypertriglyceridemia;
伴高甘油三酯血症的2型糖尿病纤溶酶原激活物抑制物-1水平变化及机制探讨
6.
A Preliminary Study on the Relationship between TM、PAI-1 and Carotid Artery Lesion in DM;
血栓调节蛋白、纤溶酶原激活物抑制物-1与糖尿病颈动脉病变的关系
7.
The clinical analysis on the homocystein and PAI-1 of 80 cases of the patients with metabolism synthesis drafts the merge apoplexy
80例代谢综合征合并脑卒中患者同型半胱氨酸及纤溶酶原激活物抑制物-1检测分析
8.
The relation of plasma plasminogen activator inhibitor activity and coronary heart disease
纤溶酶原激活抑制物活性与冠心病发病关系
9.
Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases
纤溶酶原激活物抑制剂-1与心血管疾病
10.
Inhibitory effect of green tea polyphenols on plasminogen activator inhibitor-1 expression
绿茶多酚对纤溶酶原激活物抑制剂-1表达影响
11.
Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;
慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
12.
The Role of the Plasminogen Activator Inhibitor-1 in the Pathogenesis of Hepatic Fibrosis;
纤溶酶原激活物抑制剂-1在肝纤维化发生中的作用
13.
Analysis of the Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Fibrinogen in Patients with Coronary Atherosclerotic Heart Disease
冠心病患者凝血酶激活的纤溶抑制物与纤维蛋白原关系分析
14.
Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells
细胞因子诱导人胸膜细胞释放纤溶酶原激活物抑制剂-1的研究
15.
Research Progress of Plasminogen Activator Inhibitor One in Gestational Diabetes Mellitus
纤溶酶原激活物抑制剂-1（PAI-1）与妊娠期糖尿病的研究
16.
Studies on the Thrombin Activatable Fibrinolysis Inhibitor of Coronary Atherosclerotic Heart Disease;
冠心病患者凝血酶激活的纤溶抑制物研究
17.
The Effect of Amiloride-an Inhibitor of Urokinase on the Pathology of Rat COPD Model;
尿激酶型纤溶酶原激活物抑制剂—氨氯吡咪对大鼠COPD模型病理改变的影响
18.
Activity of plasma tissue plasminogen activator and plasminogen activator inhibitor in patients with hypertensive disorder complicating pregnancy
妊娠期高血压疾病患者血浆组织型纤溶酶原激活物及其抑制物的活性变化